HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Nonprofit Pharmaceutical Companies

485.302

-11.412-2.30%

Number of Gainers:7

Number of Losers:24

Number of Flat:2

PE:- -

High:496.758

Open:496.758

Low:480.418

Close:496.758

Volume:66.29M

Turnover:1.57B

Market Cap:308.07B

Float Cap:274.58B

Loading ...

Hong Kong Stock Market Movers: HBM Holdings-B (02142) Climbs Over 4% in Morning Session After Positive Asthma Trial Results and Stock Connect Inclusion

Ascletis Hits 4-Week High on Initiating US Phase I Study on Obesity Drug

How Traditional Chinese Medicine Is Moving From Ancient Recipes to Evidence-Based Data

TYK Medicines-B Chairman, President and CEO Wu Yusheng Plans Share Purchase

HBM Holdings' Asthma Therapy Shows Promising Phase II Results and Moves to Phase III

Chengdu Easton Biopharmaceuticals Schedules Participation in Semi-Annual Innovation Drug Sector Earnings Call

HBM Says Partner Windward Bio Starts Phase 3 Asthma Trial of Twice-Yearly TSLP Antibody Hbm9378/win378

Hbm9378/Win378, an Ultra-Long-Acting Antibody Targeting Tslp, Achieves Positive Phase 2 Results in Asthma and Initiates Phase 3 Study

THOMSON REUTERS

Genfleet-B Completes Share Buyback Worth HK$1.54 Million

The AI Drug Discovery Sector Enters Its Value-Realization Phase, Unlocking Fresh Growth Avenues for Innovative Medicines

ALEBUND-B Wins US FDA Nod to Start Trial of Novel IgA Nephropathy Drug AP308

Alphamab-B Repurchases 220,000 Shares for HK$1.85 Million on September 8

Alphamab Oncology Files HKEX Next-Day Return Disclosing Share Repurchase at HKD 8.41

Ionis Pharmaceuticals Shares Slide 13.1% in Pre-Market Trading

ASC36 Obesity Therapy Enters Phase I Trials in the US by Ascletis

Ascletis Pharma - Initiates U.S. Phase I Study for Asc36 Oral Tablets for Obesity

THOMSON REUTERS

Consolidation at the Base Meets Trend Rebound: When Will Kintor Pharma-B Hit the Key Turning Point for a Valuation Recovery?

Nanxin Pharmaceutical Receives Penalty for Disclosure Violations, Affected Investors May Seek Compensation

InnoCare Gets First Half of Remaining Stake Bought in Subsidiary

MT Newswires Live

HK Market Alert: Biocytogen-B (02315) Surges Over 10% in Afternoon Trade Following Exclusive Licensing Agreement with Qilu Pharmaceutical

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrzen.com/stock/BK1574/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"Nonprofit Pharmaceutical Companies","latestPrice":485.34595,"timestamp":1789105190905,"preClose":496.75812,"halted":0,"volume":66302561,"delay":0,"changeRate":-0.022973,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":-11.41217,"latestTime":"09-11 13:39:53","open":496.75812,"high":496.75812,"low":480.41833,"amount":1569767067,"amplitude":0.032893,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1789114200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1789090200000,1789099200000],[1789102800000,1789113600000]],"pbRate":3.703217,"peRate":164.740195,"turnoverRate":0.002523,"increases":7,"decrements":24,"flats":1,"marketCap":308074040976,"floatMarketCap":274580258152},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":496.75812,"amplitude":0.032893,"preClose":496.75812,"low":480.41833,"pbRate":"3.703217","latestPrice":485.30203,"volume":66288561,"delay":0,"open":496.75812,"prevYearClose":556.26263,"prevWeekClose":532.025,"prevMonthClose":503.398,"prevQuarterClose":453.519,"fiveDayClose":532.025,"twentyDayClose":518.327,"sixtyDayClose":434.471,"secType":"PLATE","market":"HK","turnoverRate":0.002522,"peRate":164.740195,"marketCap":308048681616,"floatMarketCap":274554898792,"timestamp":1789105187199,"nameCN":"Nonprofit Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":7,"down":24,"flat":2},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1141984241","title":"Hong Kong Stock Market Movers: HBM Holdings-B (02142) Climbs Over 4% in Morning Session After Positive Asthma Trial Results and Stock Connect Inclusion","url":"https://stock-news.laohu8.com/highlight/detail?id=1141984241","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141984241?lang=en_us&edition=fundamental","pubTime":"2026-09-09 10:42","pubTimestamp":1788921769,"startTime":"0","endTime":"0","summary":"Shares of HBM Holdings-B (02142) surged more than 4% during Tuesday's morning trading session, with the stock last changing hands at HK$15.23, up 4.67%, on turnover of approximately HK$59.8...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142","BK1583","BK4585","BK1574","BK1161","KCAI","BK4588","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666309337","title":"Ascletis Hits 4-Week High on Initiating US Phase I Study on Obesity Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2666309337","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666309337?lang=en_us&edition=fundamental","pubTime":"2026-09-09 10:03","pubTimestamp":1788919398,"startTime":"0","endTime":"0","summary":"BUZZ-Ascletis hits 4-week high on initiating US Phase I study on obesity drug** Shares of Ascletis Pharma Inc1672.HKclimb 5.6% to HK$10.75, their highest since August 13** Stock on track for biggest one-day pct gain since August 7** Pharmaceutical products producer says it hasinitiateda U.S. Phase I study of ASC36 oral tablets for treatment of obesity after receiving Investigational New Drug clearance from the U.S. Food and Drug Administration** ASC36 oral tablets reduced mean body weight up to 13.2% from baseline after once-daily dosing for seven days in non-human primates - co** YTD, stock down 7.3%, while Hang Seng Biotech Index.HSBIOup 10.7%","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nL1N451020:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1515","BK1574","01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186275720","title":"How Traditional Chinese Medicine Is Moving From Ancient Recipes to Evidence-Based Data","url":"https://stock-news.laohu8.com/highlight/detail?id=1186275720","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186275720?lang=en_us&edition=fundamental","pubTime":"2026-09-09 07:41","pubTimestamp":1788910867,"startTime":"0","endTime":"0","summary":"Traditional Chinese Medicine (TCM) has long been built on the accumulated wisdom of generations of physicians. However, when measured against the rigorous standards of modern medicine, the industry...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4159","MEDX","BK1161","RCT","IBBQ","BK1574","LNGR","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136667600","title":"TYK Medicines-B Chairman, President and CEO Wu Yusheng Plans Share Purchase","url":"https://stock-news.laohu8.com/highlight/detail?id=1136667600","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136667600?lang=en_us&edition=fundamental","pubTime":"2026-09-08 21:26","pubTimestamp":1788873985,"startTime":"0","endTime":"0","summary":"TYK Medicines-B (02410) has announced that its Chairman, Executive Director and President, Dr. Wu Yusheng, has informed the company of his recent share purchases in the open market. Dr. Wu may...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09939","02410","BK1161","BK1574","159938","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167922243","title":"HBM Holdings' Asthma Therapy Shows Promising Phase II Results and Moves to Phase III","url":"https://stock-news.laohu8.com/highlight/detail?id=1167922243","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167922243?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:58","pubTimestamp":1788872333,"startTime":"0","endTime":"0","summary":"HBM HOLDINGS-B (02142) has announced that its partner, Windward Bio AG, has reported positive interim results from the Phase II portion of the POLARIS-1 clinical trial evaluating HBM9378/WIN378 for...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1583","02142","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154956841","title":"Chengdu Easton Biopharmaceuticals Schedules Participation in Semi-Annual Innovation Drug Sector Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=1154956841","media":"Deep News","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154956841?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:52","pubTimestamp":1788871964,"startTime":"0","endTime":"0","summary":"Chengdu Easton Biopharmaceuticals Co.,Ltd. (SSE: 688513) announced on September 8 that it will take part in the Science and Technology Innovation Board's collective earnings briefing for the...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","KSTR","LNGR","159992","688513","BK1161","06978","IBBQ","MEDX","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665320273","title":"HBM Says Partner Windward Bio Starts Phase 3 Asthma Trial of Twice-Yearly TSLP Antibody Hbm9378/win378","url":"https://stock-news.laohu8.com/highlight/detail?id=2665320273","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665320273?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:18","pubTimestamp":1788869907,"startTime":"0","endTime":"0","summary":"HBM says partner Windward Bio starts Phase 3 asthma trial of twice-yearly TSLP antibody HBM9378/WIN378HBM Holdings highlighted positive interim Phase 2 asthma results for HBM9378/WIN378, an ultra-long","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDL4WknG1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02142","BK1574","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665320213","title":"Hbm9378/Win378, an Ultra-Long-Acting Antibody Targeting Tslp, Achieves Positive Phase 2 Results in Asthma and Initiates Phase 3 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2665320213","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665320213?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:17","pubTimestamp":1788869848,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nTUA60HVBV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02142","BK1574","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126663144","title":"Genfleet-B Completes Share Buyback Worth HK$1.54 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1126663144","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126663144?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:11","pubTimestamp":1788869514,"startTime":"0","endTime":"0","summary":"On September 8, 2026, GENFLEET-B (02595) announced that it had repurchased a total of 57,000 shares at a cost of HK$1.5418 million.The buyback was executed in accordance with the company's existing...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159938","09939","BK1515","02595","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190517580","title":"The AI Drug Discovery Sector Enters Its Value-Realization Phase, Unlocking Fresh Growth Avenues for Innovative Medicines","url":"https://stock-news.laohu8.com/highlight/detail?id=1190517580","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1190517580?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:10","pubTimestamp":1788869456,"startTime":"0","endTime":"0","summary":"The AI-driven pharmaceutical industry has moved past its early-stage concept hype, with validation levels steadily climbing. The narrative has shifted from algorithmic promise to tangible pipeline...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","IBBQ","QTOC","AGIX","AIPO","LNGR","159992","MEDX","CHAT","06978","01477","VTHR","BK1574","ARTY","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141807270","title":"ALEBUND-B Wins US FDA Nod to Start Trial of Novel IgA Nephropathy Drug AP308","url":"https://stock-news.laohu8.com/highlight/detail?id=1141807270","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141807270?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:06","pubTimestamp":1788869176,"startTime":"0","endTime":"0","summary":"ALEBUND-B (09637) has announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for AP308, a first-in-class engineered recombinant IgA...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159938","IBBJ","09939","PSYK","159151","MDTX","BK1515","09637","BK1191","BK1161","BMED","IBBQ","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175433190","title":"Alphamab-B Repurchases 220,000 Shares for HK$1.85 Million on September 8","url":"https://stock-news.laohu8.com/highlight/detail?id=1175433190","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175433190?lang=en_us&edition=fundamental","pubTime":"2026-09-08 19:28","pubTimestamp":1788866893,"startTime":"0","endTime":"0","summary":"ALPHAMAB-B (09966) announced that it spent HK$1.8499 million to buy back 220,000 shares on September 8, 2026.The repurchase reflects the company's ongoing commitment to enhancing shareholder value through strategic capital management initiatives.","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","09966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665323327","title":"Alphamab Oncology Files HKEX Next-Day Return Disclosing Share Repurchase at HKD 8.41","url":"https://stock-news.laohu8.com/highlight/detail?id=2665323327","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665323327?lang=en_us&edition=fundamental","pubTime":"2026-09-08 19:25","pubTimestamp":1788866733,"startTime":"0","endTime":"0","summary":"Alphamab Oncology files HKEX next-day return disclosing share repurchase at HKD 8.41Alphamab Oncology repurchased 220,000 shares on Sept. 8 for treasury, no cancellations disclosed.Buyback price range","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDL8Tygqr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143453518","title":"Ionis Pharmaceuticals Shares Slide 13.1% in Pre-Market Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1143453518","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143453518?lang=en_us&edition=fundamental","pubTime":"2026-09-08 19:20","pubTimestamp":1788866449,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals shares dropped 13.1% in pre-market trading on September 8, according to market data.  The decline reflects a sharp investor reaction to recent developments, though specific...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1191","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164928784","title":"ASC36 Obesity Therapy Enters Phase I Trials in the US by Ascletis","url":"https://stock-news.laohu8.com/highlight/detail?id=1164928784","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164928784?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:06","pubTimestamp":1788861983,"startTime":"0","endTime":"0","summary":"Ascletis Pharma-B (01672) has announced the initiation of its Phase I clinical study in the United States for ASC36, an oral amylin receptor agonist peptide designed to treat obesity, following...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","01672","01477","BK1191","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665932180","title":"Ascletis Pharma - Initiates U.S. Phase I Study for Asc36 Oral Tablets for Obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=2665932180","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665932180?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:01","pubTimestamp":1788861676,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nFWN44Z0L3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","01672","BK1574","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150107003","title":"Consolidation at the Base Meets Trend Rebound: When Will Kintor Pharma-B Hit the Key Turning Point for a Valuation Recovery?","url":"https://stock-news.laohu8.com/highlight/detail?id=1150107003","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150107003?lang=en_us&edition=fundamental","pubTime":"2026-09-08 16:48","pubTimestamp":1788857312,"startTime":"0","endTime":"0","summary":"On the morning of September 7, KINTOR PHARMA-B (09939) announced that its human long-term safety trial for KT-939, a novel and highly effective tyrosinase inhibitor developed in-house to suppress...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","BK1515","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101281013","title":"Nanxin Pharmaceutical Receives Penalty for Disclosure Violations, Affected Investors May Seek Compensation","url":"https://stock-news.laohu8.com/highlight/detail?id=1101281013","media":"Deep News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101281013?lang=en_us&edition=fundamental","pubTime":"2026-09-08 15:31","pubTimestamp":1788852662,"startTime":"0","endTime":"0","summary":"Nanxin Pharmaceutical has been found to have disclosed inaccurate financial data in its annual report. On August 13, 2026, the company officially received the Administrative Penalty Decision issued...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01477","BK1191","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665476053","title":"InnoCare Gets First Half of Remaining Stake Bought in Subsidiary","url":"https://stock-news.laohu8.com/highlight/detail?id=2665476053","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665476053?lang=en_us&edition=fundamental","pubTime":"2026-09-08 14:15","pubTimestamp":1788848135,"startTime":"0","endTime":"0","summary":"InnoCare Pharma  received the first half of the 7% stake of Guangzhou InnoCare Pharma Technology, according to a Shanghai bourse filing on Tuesday.Guangzhou InnoCare completed the changes in its industry and commerce registration after its parent received its 3.5% stake.InnoCare bought the remaining 7% of Guangzhou InnoCare for 476.3 million yuan in August.The pharmaceutical company's shares slipped 1% during the afternoon trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","BK1161","09969","BK1574","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170187220","title":"HK Market Alert: Biocytogen-B (02315) Surges Over 10% in Afternoon Trade Following Exclusive Licensing Agreement with Qilu Pharmaceutical","url":"https://stock-news.laohu8.com/highlight/detail?id=1170187220","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170187220?lang=en_us&edition=fundamental","pubTime":"2026-09-08 14:00","pubTimestamp":1788847256,"startTime":"0","endTime":"0","summary":"Biocytogen-B (02315) saw its shares jump more than 10% in the afternoon session, last trading up 8.71% at HK$63 with turnover reaching HK$129 million.According to the company's official WeChat...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02315","688796","KCAI","VXUS","01477","BK0216","BK4588","BK1191","BK1574","BK4585"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":13,"pageCount":3,"totalSize":257,"code":"91000000","status":"200"}]}}